Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | LIPE | Q05469 | 3/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.34 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8219454 | 0.87 | AAK1 (0.39) | AAK1LIPEPRMT5WDR77KCNQ4 | |
| SCHEMBL1055632 | 0.83 | AAK1 (0.45) | AAK1LIPEPRMT5WDR77HSP90AA1 | |
| SCHEMBL1063614 | 0.83 | LIPE (0.49) | AAK1LIPEPRMT5WDR77HSP90AA1 | |
| SCHEMBL8219634 | 0.83 | LIPE (0.37) | LIPE | |
| SCHEMBL29984550 | 0.81 | AAK1 (0.41) | AAK1LIPEPRMT5WDR77KCNQ4 | |
| SCHEMBL16263673 | 0.81 | AAK1 (0.41) | AAK1LIPEPRMT5WDR77KCNQ4 | |
| SCHEMBL30985621 | 0.80 | PRMT5 (0.39) | AAK1LIPEPRMT5WDR77KCNQ4 | |
| SCHEMBL31736379 | 0.80 | AAK1 (0.40) | AAK1LIPEPRMT5WDR77KCNQ4 | |
| SCHEMBL31534338 | 0.79 | AAK1 (0.36) | AAK1LIPEPRMT5WDR77KCNQ4 | |
| SCHEMBL1063815 | 0.79 | KCNQ4 (0.41) | AAK1LIPEPRMT5WDR77KCNQ4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49556-E1 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-06-20 | — | — | US | claimed |
| US-8501758-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-08-06 | — | — | US | claimed |
| EP-2470526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-07-04 | — | — | EP | claimed |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-15 | — | — | US | claimed |
| WO-2011025927-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | WO | claimed |
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2024-12-12 | — | — | US | disclosed |
| US-RE49556-E1 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-RE49556-E1 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230116233-A1 | Compounds And Compositions As Protein Kinase Inhibitors | ARRAY BIOPHARMA INC (US) | 2023-04-13 | — | — | US | disclosed |
| US-20200323852-A1 | Compounds And Compositions As Protein Kinase Inhibitors | IRM LLC (BM) | 2020-10-15 | — | — | US | disclosed |
| US-20200323852-A1 | Compounds And Compositions As Protein Kinase Inhibitors | IRM LLC (BM) | 2020-10-15 | — | — | US | disclosed |
| US-10576080-B2 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20130296318-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130296318-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8501758-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-08-06 | — | — | US | disclosed |
| US-8501758-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-08-06 | — | — | US | disclosed |
| EP-2470526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-07-04 | — | — | EP | disclosed |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-15 | — | — | US | disclosed |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-15 | — | — | US | disclosed |
| WO-2011025927-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200323852-A1 | Compounds And Compositions As Protein Kinase Inhibitors | BRAF, RAF1, ARAF | AAK1 271/4885LIPE 3394/4885PRMT5 1345/4885 |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | AAK1 271/4885LIPE 3394/4885PRMT5 1345/4885 |
| US-20130296318-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | AAK1 271/4885LIPE 3394/4885PRMT5 1345/4885 |
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | FGFR3, FGFR1, ERBB3 | AAK1 205/4885LIPE 4333/4885PRMT5 780/4885 |
| US-20230116233-A1 | Compounds And Compositions As Protein Kinase Inhibitors | BRAF, RAF1, ARAF | AAK1 271/4885LIPE 3394/4885PRMT5 1345/4885 |
| US-10576080-B2 | Compounds and compositions as protein kinase inhibitors | BRAF, RAF1, ARAF | AAK1 271/4885LIPE 3394/4885PRMT5 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.